FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024194401> ?p ?o ?g. }

• W2024194401 abstract "In Germany pancreatic cancer remains a lethal disease with only 3 - 8% of patients surviving 5 years after diagnosis of the tumor (2005). Reasons for this poor situation are advanced and inoperable tumor stages at time of diagnosis and resistance to conventional therapies. One bottleneck in the development of novel therapies is the restricted availability of preclinical models with a high clinical relevance. The aim of our study was to develop well-defined in vivo xenografts derived from patient pancreatic carcinomas to address translational questions. These xenografts can be used for identification of biomarkers and cancer related pathways as well as for the evaluation of targeted therapies. The genesis of pancreatic neoplasm, the progression of tumor growth as wells as the development of resistance can be elucidated with animal models of patient-derived material. And last but not least preclinical data can be used prospectively for efficient stratification of patients. 57 patient tumors were collected from the clinical cooperation partner and transplanted immediately into immune-deficient mice. 14 out of 57 samples could be established so far as passagable pancreatic cancer xenografts (PDX), 5 were identified as inflammations of the pancreas. Interestingly, we observed 4 out of 57 as post-transplant lymphoproliferative disorders (PLTD); 29 failed to grow in mice. All of the engrafted PDX are poor or moderate differentiated adenocarcinomas. Global gene expression analysis and determination of cancer associated mutations were performed from engrafted tumor models. According to clinical data we found K-ras mutations in 13 and additionally p53 mutations in 9 out of 14 PDX. Chemosensitivity was evaluated by transplanting tumor material into cohorts of immune-deficient mice. Beginning from palpable tumor sizes mice were treated with clinically relevant therapies (Gemcitabine, Abraxane, 5FU, Oxaliplatin, Erlotinib as monotherapy or combinations) as well as PDAC untypical drugs like Irinotecan, Vincristine, Avastin and Sorafenib at optimized schedules and doses. The response to Gemcitabine was moderate within the PDX panel. The most efficient therapeutic was Abraxane. Additionally, we could establish a luciferase expressing PDX for in vivo imaging of orthotopic tumor grafts. Patient-derived xenografts are a crucial tool for the prediction of therapy and potentially relevant for the implication into clinical decisions. We have successfully developed a panel of 14 pancreatic cancer PDX for translational research projects. Citation Format: Diana Behrens, Diana Anders, Cora Hallas, Jessica Pahle, Iduna Fichtner. In vivo models of pancreatic cancer for translational medicine. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A100." @default.
• W2024194401 created "2016-06-24" @default.
• W2024194401 creator A5003244386 @default.
• W2024194401 creator A5015081490 @default.
• W2024194401 creator A5039652183 @default.
• W2024194401 creator A5042386057 @default.
• W2024194401 creator A5056101308 @default.
• W2024194401 date "2015-12-01" @default.
• W2024194401 modified "2023-09-26" @default.
• W2024194401 title "Abstract A100: In vivo models of pancreatic cancer for translational medicine" @default.
• W2024194401 doi "https://doi.org/10.1158/1535-7163.targ-15-a100" @default.
• W2024194401 hasPublicationYear "2015" @default.
• W2024194401 type Work @default.
• W2024194401 sameAs 2024194401 @default.
• W2024194401 citedByCount "0" @default.
• W2024194401 crossrefType "proceedings-article" @default.
• W2024194401 hasAuthorship W2024194401A5003244386 @default.
• W2024194401 hasAuthorship W2024194401A5015081490 @default.
• W2024194401 hasAuthorship W2024194401A5039652183 @default.
• W2024194401 hasAuthorship W2024194401A5042386057 @default.
• W2024194401 hasAuthorship W2024194401A5056101308 @default.
• W2024194401 hasConcept C121608353 @default.
• W2024194401 hasConcept C126322002 @default.
• W2024194401 hasConcept C128544194 @default.
• W2024194401 hasConcept C142724271 @default.
• W2024194401 hasConcept C143998085 @default.
• W2024194401 hasConcept C150903083 @default.
• W2024194401 hasConcept C207001950 @default.
• W2024194401 hasConcept C2778764654 @default.
• W2024194401 hasConcept C2780210213 @default.
• W2024194401 hasConcept C2780635560 @default.
• W2024194401 hasConcept C2911091166 @default.
• W2024194401 hasConcept C502942594 @default.
• W2024194401 hasConcept C60644358 @default.
• W2024194401 hasConcept C71924100 @default.
• W2024194401 hasConcept C86803240 @default.
• W2024194401 hasConceptScore W2024194401C121608353 @default.
• W2024194401 hasConceptScore W2024194401C126322002 @default.
• W2024194401 hasConceptScore W2024194401C128544194 @default.
• W2024194401 hasConceptScore W2024194401C142724271 @default.
• W2024194401 hasConceptScore W2024194401C143998085 @default.
• W2024194401 hasConceptScore W2024194401C150903083 @default.
• W2024194401 hasConceptScore W2024194401C207001950 @default.
• W2024194401 hasConceptScore W2024194401C2778764654 @default.
• W2024194401 hasConceptScore W2024194401C2780210213 @default.
• W2024194401 hasConceptScore W2024194401C2780635560 @default.
• W2024194401 hasConceptScore W2024194401C2911091166 @default.
• W2024194401 hasConceptScore W2024194401C502942594 @default.
• W2024194401 hasConceptScore W2024194401C60644358 @default.
• W2024194401 hasConceptScore W2024194401C71924100 @default.
• W2024194401 hasConceptScore W2024194401C86803240 @default.
• W2024194401 hasLocation W20241944011 @default.
• W2024194401 hasOpenAccess W2024194401 @default.
• W2024194401 hasPrimaryLocation W20241944011 @default.
• W2024194401 hasRelatedWork W1975597047 @default.
• W2024194401 hasRelatedWork W1997946609 @default.
• W2024194401 hasRelatedWork W2036746 @default.
• W2024194401 hasRelatedWork W2057494314 @default.
• W2024194401 hasRelatedWork W2158811570 @default.
• W2024194401 hasRelatedWork W2318451339 @default.
• W2024194401 hasRelatedWork W2319222851 @default.
• W2024194401 hasRelatedWork W2332618044 @default.
• W2024194401 hasRelatedWork W2501053017 @default.
• W2024194401 hasRelatedWork W2769260826 @default.
• W2024194401 hasRelatedWork W2791981903 @default.
• W2024194401 hasRelatedWork W2810010855 @default.
• W2024194401 hasRelatedWork W3011458302 @default.
• W2024194401 hasRelatedWork W3017849569 @default.
• W2024194401 hasRelatedWork W3077207536 @default.
• W2024194401 hasRelatedWork W3083755930 @default.
• W2024194401 hasRelatedWork W3088791280 @default.
• W2024194401 hasRelatedWork W3097010571 @default.
• W2024194401 hasRelatedWork W3121390208 @default.
• W2024194401 hasRelatedWork W3194821601 @default.
• W2024194401 isParatext "false" @default.
• W2024194401 isRetracted "false" @default.
• W2024194401 magId "2024194401" @default.
• W2024194401 workType "article" @default.